Though the detail is not readily available, it does seem that in October 2018, there was a merger/acquisition transaction involving San Diego based Gossamer Bio (fdba FSG, Bio, Inc) and Adhaere Pharmaceuticals, Inc. The latter has been identifed as a privately held company developing novel small molecule therapeutics for the treatment of inflammatory and autoimmune diseases. The company's approach organized around a unique way of targeting adhesion receptors on leukocytes. Adhaere has also created a broadly applicable proprietary technology platform for discovery of a pipeline of novel therapeutics. With one small trache of folllow-on funding on completion of Phase I in 2016, no additional SBIR allocation is reported as having been made.
